InMed Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
INM InMed Pharmaceuticals Inc
NSTG NanoString Technologies Inc
ORCL Oracle Corp
OPTT Ocean Power Technologies Inc
SPEYF Spey Resources Corp
BCTX Briacell Therapeutics Corp
JAZZ Jazz Pharmaceuticals PLC
KRT Karat Packaging Inc
REMRF Red Moon Resources Inc
ARR ARMOUR Residential REIT Inc
Go

Health Care : Pharmaceuticals | Small Cap Value
Based in Canada
Company profile

InMed Pharmaceuticals Inc. is a pre-clinical-stage biopharmaceutical company. The Company specializes in the research and development of cannabinoid-based therapies combined with drug delivery systems. The Company operates through the segment of research and development of pharmaceutical cannabis based-therapies. The Company is working on two products, which include INM-750, for the treatment of Epidermolysis Bullosa (EB), and INM-085, for the treatment of Glaucoma. The INM-750 is a therapy developed for EB designed specifically to modulate disease activity and to alleviate symptoms. The INM-085 is designed as a dual-action cannabinoid ocular therapy. INM-085 is designed as a topical formulation to be administered directly to the eye. It is working on the development of several cannabinoid-based treatments for multiple diseases, including ocular, dermatology, cancer, inflammation, pain and arthritis disease areas. Its subsidiary is Biogen Sciences Inc. (BSI).

The symbol you entered, IMLFF, changed to INM.

Price
Delayed
$2.80
Day's Change
0.05 (1.82%)
Bid
--
Ask
--
B/A Size
--
Day's High
2.80
Day's Low
2.76
Volume
1,694

Display:

Providers:

UpdateCancel
6 providers
June 17, 2021
InMed Pharmaceuticals Increases Cannabinoid Yield to 5 g/L with IntegraSyn(TM) in Advance of Commercial Scale Production

InMed Pharmaceuticals Inc. ("InMed" or the "Company") (Nasdaq: INM), a clinical-stage company developing cannabinoid-based pharmaceutical drug candidates as well as manufacturing technologies for pharmaceutical-grade rare cannabinoids, today...(Globe Newswire)

June 09, 2021
InMed Pharmaceuticals to Present at the 2021 BIO Digital Conference

InMed Pharmaceuticals Inc. ("InMed" or the "Company") (Nasdaq: INM), a clinical-stage company developing cannabinoid-based pharmaceutical drug candidates and leading the clinical development of cannabinol ("CBN"), today announced that Eric. A...(Globe Newswire)

May 13, 2021
InMed Pharmaceuticals, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / May 13, 2021 / InMed Pharmaceuticals, Inc. (NASDAQ:INM) will be discussing their earnings results in their 2021 Third Quarter Earnings call to be held on May 13, 2021 at 11:00 AM Eastern Time. (Accesswire)

InMed Pharmaceuticals Reports Third Quarter Fiscal 2021 Financial Results

InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ:INM), a clinical-stage company developing pharmaceutical-based drug candidates and leading the way in the clinical development of cannabinol ("CBN"), today reported financial results for...(Globe Newswire)

May 06, 2021
InMed Pharmaceuticals to Report Third Quarter Fiscal 2021 Financial Results

InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ:INM; TSX:IN), a clinical-stage company developing pharmaceutical-based drug candidates and leading the way in the clinical development of cannabinol ("CBN"), will report financial...(Globe Newswire)

May 04, 2021
InMed to Present at Canaccord Genuity's 5th Annual Global Cannabis Conference on May 11th, 2021

InMed Pharmaceuticals Inc. ("InMed" or the "Company") (Nasdaq: INM; TSX:IN), a clinical-stage company developing cannabinoid-based pharmaceutical drug candidates and leading the clinical development of cannabinol ("CBN"), today announced that Eric...(Globe Newswire)

April 28, 2021
InMed Pharmaceuticals Submits Clinical Trial Applications to Evaluate INM-755 (Cannabinol) Cream in a Phase 2 Trial for Epidermolysis Bullosa

-- Filings submitted in Austria, Israel, and Serbia for a Phase 2 Clinical Trial with INM-755 cream -- Additional submissions slated for France, Germany, Greece, and Italy over the next several days and weeks. (Globe Newswire)

April 27, 2021
InMed Pharmaceuticals Announces Voluntary Delisting from TSX

InMed Pharmaceuticals Inc. ("InMed" or the "Company") (Nasdaq:INM) (TSX:IN), a clinical-stage company developing cannabinoid-based pharmaceutical drug candidates and leading the clinical development of cannabinol ("CBN"), today announced that...(Globe Newswire)

April 26, 2021
InMed Pharmaceuticals Achieves 2g/L Cannabinoid Yield with IntegraSyn(TM)

InMed Pharmaceuticals Inc. ("InMed" or the "Company") (Nasdaq: INM; TSX:IN), a clinical-stage company developing cannabinoid-based pharmaceutical drug candidates and leading the clinical development of cannabinol ("CBN"), today announced that its...(Globe Newswire)

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.